Treatment of motor symptoms in parkinson's disease;Tratamiento de los síntomas motores en la enfermedad de Parkinson

Revista de Neurologia

Volumn 48, Issue SUPPL. 1, 2009, Pages

  Moris De La Tassa G ^a   Arias Rodriguez M ^a  

^a HOSPITAL SAN AGUSTÍN   (Spain)

Author keywords

Antiparkinsonian agents; Catechol o methyltransferase inhibitors; Deep brain stimulation; Dopamine agonists; Monoamine oxidase inhibitors; Parkinson's disease

Indexed keywords

AMANTADINE; APO GO PEN; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DONEPEZIL; ENTACAPONE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SOGILEN; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

CLINICAL FEATURE; HUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGENTS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 62549148564     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.48s01.2008742     Document Type: Review

References (16)

1. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 968-75.
2. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-95.
3. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Dis order Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-85.
4. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-202.
5. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2: 382-92.
6. Martínez-Corral M, Kulisevsky J. Pramipexol y enfermedad de Parkinson, una actualización. Rev Neurol 2008; 46: 49-52.
7. Vivancos-Matellano F. Ropinirol en el tratamiento de la enfermedad de Parkinson: actualización. Rev Neurol 2006; 42: 542-8.
8. Ruiz-Huete C, Bermejo PE, Terrón C, Anciones B. Rotigotina en el tra tamiento de la enfermedad de Parkinson. Experiencia sobre una muestra de 150 pacientes. Rev Neurol 2008; 46: 257-60.
9. Giménez-Roldán S, García-Muñozguren S. Uso de apomorfina en la enfermedad de Parkinson. Rev Neurol 2002; 35: 668-74.
10. Litvan I. Nuevas perspectivas en la enfermedad de Parkinson. Rev Neurol 1999; 29: 139-45.
11. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007; 2: 234-43.
12. Schapira AH. Rasagiline in neurodegeneration. Exp Neurol 2008; 212: 255-7.
13. Hernando-Requejo V, Pastor J, Peña E, Carrasco-Moro R, Pedrosa-Sánchez M, Pulido-Rivas P, et al. Estimulación subtalámica unilateral en el tratamiento de la enfermedad de Parkinson avanzada. Rev Neurol 2008; 46: 18-23.
14. Weiner WJ, Reich SG. Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough. Neurology 2008; 71: 470-1.
15. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in Parkinson's disease. Neurology 2008; 71: 474-80.
16. Linazasoro G. Inicio de la terapia dopaminergica en la enfermedad de Parkinson: seis buenas razones para retrasarlo. Neurologia 2008; 23: 299-305.